HSBC Holdings
EGRX

HSBC Holdings’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

HSBC Holdings’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,396
Closed -$45K – 3287
2024
Q3 		$45K Sell
11,396
-1,752
-13% -$8.36K ﹤0.01% 2890
2024
Q2 		$66.3K Sell
13,148
-29
-0.2% -$126 ﹤0.01% 2794
2024
Q1 		$69K Buy
13,177
+1,179
+10% +$6.47K ﹤0.01% 2902
2023
Q4 		$63K Buy
+11,998
New +$118K ﹤0.01% 2635
2021
Q1 		– Sell
-8,485
Closed -$394K – 3200
2020
Q4 		$394K Sell
8,485
-487
-5% -$22.8K ﹤0.01% 2362
2020
Q3 		$381K Buy
8,972
+1,351
+18% +$59.1K ﹤0.01% 2109
2020
Q2 		$366K Buy
7,621
+3,235
+74% +$161K ﹤0.01% 2028
2020
Q1 		$202K Sell
4,386
-552
-11% -$27.7K ﹤0.01% 2295
2019
Q4 		$297K Sell
4,938
-5,483
-53% -$327K ﹤0.01% 2551
2019
Q3 		$590K Buy
+10,421
New +$586K ﹤0.01% 2233

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

HSBC Holdings's EGRX Position: Q4 2024 in Review

HSBC Holdings sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 11,396 shares — an estimated $45K sold.

HSBC Holdings first reported a position in EGRX in Q3 2019 and held it in 10 quarters. The position peaked at $590K in Q3 2019. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • HSBC Holdings reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • HSBC Holdings sold 11,396 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $45K.
  • HSBC Holdings first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2019 and held it in 10 quarters.
  • HSBC Holdings's Eagle Pharmaceuticals, Inc. position peaked at $590K in Q3 2019.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on HSBC Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.